A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer-Reference-Cited by-同舟云学术

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer

Published:2023-06 Issue:3 Volume:8 Page:101173
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Galffy G.,Lugowska I.,Poddubskaya E.V.,Cho B.C.,Ahn M.-J.,Han J.-Y.,Su W.-C.,Hauke R.J.,Dyar S.H.,Lee D.H.,Serwatowski P.,Estelles D.L.,Holden V.R.,Kim Y.J.,Vladimirov V.,Horvath Z.,Ghose A.,Goldman A.,di Pietro A.,Wang J.,Murphy D.A.,Alhadab A.,Laskov M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference44 articles.

1. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

2. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer;Hellmann;N Engl J Med,2019

3. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial;Kaufman;Lancet Oncol,2016

4. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019

5. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma;Powles;N Engl J Med,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of targeted therapies for advanced urothelial carcinoma;Exploration of Targeted Anti-tumor Therapy;2024-06-21

2. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials;Frontiers in Immunology;2023-08-08